NovoCure Ltd (NVCR) stock
Close on Nov 12, 2026Market cap $1.37BP/E –Yield –
NovoCure Ltd grew revenue 12.9% to $725.39M over the twelve months to Sep 30, 2026. Free cash flow was -$24.61M. At the latest close the market valued the company at $1.37B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.37B
- P/E ratio
- –
- Price to sales
- 1.89
- Price to book
- 3.91
- Dividend yield
- –
- Free cash flow yield
- -1.80%
Fundamentals
- Revenue
- $725.39M
- Net income
- -$121.73M
- EPS, diluted
- -$1.06
- Free cash flow
- -$24.61M
- Book value per share
- $3.00
- Diluted shares
- 117M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $11.99
- Open
- $11.84
- Day's range
- $11.63 – $12.11
- Volume
- 1,246,673
- Average volume (20 days)
- 1,978,758
- Beta (5 years)
- 1.57
- 52-week range
- $9.82 – $21.45
- RSI (14 days)
- 32.4
- Volatility (1 year)
- 80.9%
- Relative volume
- 0.79×
- WACC
- 12.6%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NVCR | S&P 500 | Difference | NVCR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.4% | -2.7% | −17.7 pts | ||
| 3 months | -33.4% | -1.7% | −31.6 pts | ||
| Year to date | -9.4% | +11.9% | −21.3 pts | ||
| 1 year | +3.2% | +12.0% | −8.8 pts | ||
| 3 years | +5.3% | +78.2% | −72.9 pts | +1.7% | +21.2% |
| 5 years | -89.8% | +73.2% | −163.1 pts | -36.7% | +11.6% |
| 10 years | +30.9% | +309.6% | −278.7 pts | +2.7% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NovoCure filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Update
- Update
About NovoCure
Surgical & Medical Instruments & Apparatus
Novocure is an oncology company that develops and commercializes therapies based on Tumor Treating Fields, a proprietary technology using electric fields to disrupt cancer cell division. Its primary commercial medical devices include Optune Gio, Optune Lua, and Optune Pax. These portable systems treat adult patients with solid tumor malignancies, specifically glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and locally advanced pancreatic cancer. The company delivers products directly to patients or through hospitals, following prescriptions from certified healthcare providers.
Company profile, executives and historyNovoCure stock: common questions
What is NovoCure's stock price?
NVCR closed at $11.72 on Nov 12, 2026, down 2.25% on the day. Over the past 52 weeks it traded between $9.82 and $21.45.
What is NovoCure's market cap?
NovoCure was worth $1.37B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NVCR's P/E ratio?
NovoCure lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.06), so it has no meaningful P/E ratio.
How much revenue does NovoCure make?
NovoCure reported revenue of $725.39M for the twelve months to Sep 30, 2026, up 12.9% from a year earlier.
Does NovoCure pay a dividend?
No. NovoCure has not paid a cash dividend over the last twelve months.
When does NovoCure report earnings next?
NovoCure is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NVCR stock performed over the past year?
Including dividends, NVCR returned +3.2% over the past year, against +12.0% for the S&P 500.
How many NVCR shares are sold short?
13M shares were sold short at the latest FINRA report, 11.39% of the float, or 6.0 days of average trading volume.
Who are NovoCure's competitors?
Companies most similar to NovoCure by business, industry and size include ARAY, ATRC, OFIX, GKOS, INSP.
See a number that looks wrong?